Picture of Advicenne SA logo

ADVIC — Advicenne SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-3.39%
3m-16.86%
6m+5.55%
1yr-38.41%
Volume Change (%)
10d/3m-49.34%
Price vs... (%)
52w High-52.18%
50d MA-5.99%
200d MA-6.01%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-75.83%
Return on Equity-217.59%
Operating Margin-599.48%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Advicenne SA EPS forecast chart

Profile Summary

ADVICENNE S.A. is a late-stage biopharmaceutical company based in France. The Company focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.

Directors

    Last Annual
    December 31st, 2020
    Last Interim
    June 30th, 2021
    Incorporated
    March 29th, 2007
    Public Since
    December 6th, 2017
    No. of Employees
    33
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    fr flag iconEuronext - Paris
    Shares in Issue
    9,924,487

    ADVIC Share Price Performance

    Similar to ADVIC

    Picture of AB Science SA logo

    AB Science SA

    fr flag iconEuronext - Paris

    Picture of Biocorp Production SA logo

    Biocorp Production SA

    fr flag iconEuronext - Paris

    Picture of Boiron SA logo

    Boiron SA

    fr flag iconEuronext - Paris

    Picture of DBV Technologies SA logo

    DBV Technologies SA

    fr flag iconEuronext - Paris

    Picture of Elsalys Biotech SAS logo

    Elsalys Biotech SAS

    fr flag iconEuronext - Paris

    FAQ

    Or unlock with your email

    Or unlock with your email